Company intelligence / Profile preview

Tvardi Therapeutics

Sugar Land, Texas, United Statestvarditherapeutics.com ↗

Ownership: Public · TVRD
Development stage: Phase 2

Overview

Tvardi's lead candidate TTI-101 showed promising results in Phase 1 trials with advanced solid tumors, demonstrating dose-linear pharmacokinetics and decreased levels of phosphotyrosine STAT3 within paired tumor biopsies. No dose-limiting toxicities or treatment-related adverse events greater than grade 3 were observed. The company is currently conducting Phase 2 trials for IPF and HCC with data readouts expected in the second half of 2025 and first half of 2026 respectively.

Therapeutic areas: OncologyPulmonologyRare DiseasesImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

tti-101

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $17.4M
Total revenue: $0
Enterprise value: $1.7M

Beyond the preview

Go deeper on Tvardi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tvardi Therapeutics.

Explore the full profile